1. Diagnostic Histopathology Of Tumors

Christopher DM Fletcher Diagnostic Histopathology of Tumours 1995 Published by Churchill Livingstone Edinburgh 0-443-042950 1358 Volume 1 & 2 1995. Price Rs 175/-.

This is yet another book dealing exclusively with the diagnostic histopathology of tumours in all systems. This is the first edition of its kind having 32 chapters divided equally into two volumes.

Forty nine authors, having rich experience in their respective fields have contributed in compiling this book. Drs Fix, Unni and Ellis, just to quote a few, have contributed to the chapters on tumours of the female genital tract, osteoarticular system and breast respectively. Special attention is also given to systems like eye, ear, neuroendocrine and skin.

Most pleasing part of this book is the liberal illustration of various lesions by high quality colour photomicrographs which gives a true picture of the tumours. There are two chapters exclusively devoted to electron microscopy (EM) and immunohistochemistry. Authors have dealt in detail about the EM picture of spindle cell tumours, round cell tumours and carcinomas. Authors have also impressed upon the role of immunohistochemistry in the diagnosis and prognosis of tumours.

Finally, this book which is comprehensive, will be very useful for all pathologists whose role is very crucial in the diagnosis of tumours, and this is more so in the field of surgical pathology where new tumour variants are emerging. These volumes will be very useful to all pathologists and a good addition to medical libraries.

Diagnostic Histopathology of Tumors. 4th edition, by Christopher D.M. Diagnose tumors with confidence with Diagnostic Histopathology of Tumors, 4th Edition. Christopher Fletcher’s renowned reference provides the advanced, expert guidance you need to evaluate and interpret even the most challenging histopathology specimens more quickly and accura.

Diagnostic Histopathology of Tumors: 2 Volume Set 4E PDF Download

Diagnose tumors with confidence with Diagnostic Histopathology of Tumors, 4th Edition. Dr. Christopher Fletcher’s renowned reference provides the advanced, expert guidance you need to evaluate and interpret even the most challenging histopathology specimens more quickly and accurately.

'A must-have for any practising surgical pathologist.'Reviewed by: PathLab.org June 2014

'I would highly recommend this text to any neuropathologist to aide their day to day practice.' Reviewed by Neuropathology and Applied Neurobiology, Apr 2015

Diagnose efficiently and effectively using diagnostic flow charts, correlations of gross appearances to microscopic findings, and differential diagnosis tables for better recognition and evaluation of similar-looking entities.
Employ immunohistochemistry, molecular and genetic diagnostic tests, and other modern techniques as well as the best morphologic diagnostic methods to effectively identify each tumor or tumor-like entity.
Utilize new, clinically important molecular genetic data and updated classification schemes to help guide treatment and targeted therapy.
Apply the latest techniques and diagnostic criteria with completely rewritten chapters on Small and Large Intestines, Heart, Larynx and Trachea, Ear, and Peritoneum. Find critical information quickly thanks to more tables and bulleted lists throughout.

In the fve-year interval since publication of Diagnostic Histopathology of Tumors, Third Edition, conventional morphologic and immunohistochemical assessment has continued to hold sway as the pre-eminent, most reliable, and most cost-effective means to provide a diagnosis, prognostic assessment, and in most cases, determination of the adequacy of excision for human tumors. Such interpretation also helps to guide therapy in many settings. The continued utility of such “traditional” technologies and interpretive skills is somewhat reassuring in the setting of the ever-widening disparities in the availability of more expensive modern technologies, such as molecular genetic diagnosis, gene expression profling, and genomics, not only (to a depressing degree) between the developed and still developing (or underdeveloped)
areas of the world, but even among different developed countries or regions.
The role of molecular diagnosis is now very well established and frmly integrated in the practice of modern surgical pathology, and is especially valuable in confrming the presence of diagnostically important gene fusions or mutations, in helping with therapeutic target identifcation and, not least, in enhancing diagnostic reproducibility and tumor classifcation schemes. Whereas some targets can be identifed immunohistochemically, mutational analysis may better enable treatment selection in some contexts, especially in the setting of treatment resistance. A more complex issue, however, in some of the developed countries (with dangerously expanding health care expenditure) is the interface between pathology and genomic medicine. Expression profling as well as whole genome sequencing are increasingly being promulgated as providing additional information of critical clinical importance—yet, at this point in time, the value of such testing has only rarely been demonstrated and validated, for example in prognostication for invasive carcinoma of the breast (Oncotype Dx and Mammaprint assays)—while most other such testing remains unvalidated, analytically or clinically, and of unproven clinical value. In particular, there are no good data confrming that identifcation of a potentially targetable mutation in a tumor type in which the role of that specifc gene has never been demonstrated represents anything more than a sophisticated (and expensive) shot in the dark. Similarly, gene expression profling as a means of identifying the primary site in metastatic carcinomas is rarely more effective than high-quality immunohistochemistry combined with morphologic expertise, is more expensive and, in any event, does not very often lead to clinically signifcant change in treatment or outcome (as many of the more treatable metastases are easily recognized by conventional means). It is troubling that many such commercial tests are being marketed directly to clinicians and patients, who are often completely unable to distinguish snake oil from clinically worthwhile testing. Although it is likely that genomic data will ultimately prove their (progressively more affordable) value, until then pathologists have a responsibility to ensure (a) that often limited patient tissue is used judiciously, and (b) that, in the routine (nontrial) setting, testing of any kind has proven clinical value that might merit action by the treating physician

Diagnostic Histopathology of Tumors: 2 Volume Set 4E PDF

Diagnostic Histopathology of Tumors 4E PDF Free Download

Diagnostic Histopathology of Tumors: 2 Volume Set 4E PDF Download

Diagnostic Histopathology Of Tumors